Tyrell J. Simkins

Tyrell J. Simkins

Auto-generated profile, based on publicly available information

Tyrell J. Simkins

Cytokinetics, Incorporated, South San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2014 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
JCJ J Credle
J J Credle
JGJ L George
J L George
JWJ Wills
J Wills
VDV Duka
V Duka
KSK Shah
K Shah
ASA Sidhu
A Sidhu
Aberrant posttranslational modifications (PTMs) of proteins, namely phosphorylation, induce abnormalities in the biological properties of recipient proteins, underlying neurological diseases including Parkinson’s disease (PD). Genome-wide studies link genes encoding α-synuclein (α-Syn) and Tau as two of the most important in the genesis of PD. Although several kinases are known to phosphorylate α-Syn and Tau, we focused our analysis on GSK-3β because of its accepted role in phosphorylating Tau and to increasing evidence supporting a strong biophysical relationship between α-Syn and Tau in PD. Therefore, we investigated transgenic mice, which express a point mutant (S9A) of human GSK-3β. GSK-3β-S9A is capable of activation through endogenous natural signaling events, yet is unable to become inactivated through phosphorylation at serine-9. We used behavioral, biochemical, and in vitro analysis to assess the contributions of GSK-3β to both α-Syn and Tau phosphorylation. Behavioral studies revealed progressive age-dependent impairment of motor function, accompanied by loss of tyrosine hydroxylase-positive (TH+ DA-neurons) neurons and dopamine production in the oldest age group. Magnetic resonance imaging revealed deterioration of the substantia nigra in aged mice, a characteristic feature of PD patients. At the molecular level, kinase-active p-GSK-3β-Y216 was seen at all ages throughout the brain, yet elevated levels of p-α-Syn-S129 and p-Tau (S396/404) were found to increase with age exclusively in TH+ DA-neurons of the midbrain. p-GSK-3β-Y216 colocalized with p-Tau and p-α-Syn-S129. In vitro kinase assays showed that recombinant human GSK-3β directly phosphorylated α-Syn at a single site, Ser129, in addition to its known ability to phosphorylate Tau. Moreover, α-Syn and Tau together cooperated with one another to increase the magnitude or rate of phosphorylation of the other by GSK-3β. Together, these data establish a novel upstream role for GSK-3β as one of several kinases associated with PTMs of key proteins known to be causal in PD.

9 April 2021 in Current Neurology and Neuroscience Reports
Verified
Journal Article
Closed access
PDF file
TSTyrell J Simkins
Tyrell J Simkins
GDGreg J Duncan
Greg J Duncan
DBDennis Bourdette
Dennis Bourdette

1 April 2008 in Neuroscience
Verified
Journal Article
Closed access
SRS. Rothstein
S. Rothstein
TST. Simkins
T. Simkins
JNJ.L. Nuñez
J.L. Nuñez

7 September 2021 in The Neuroradiology Journal
Verified
Journal Article
Closed access
PDF file
GSGhazal Shadmani
Ghazal Shadmani
TSTyrell J Simkins
Tyrell J Simkins
RAReza Assadsangabi
Reza Assadsangabi
MAMichelle Apperson
Michelle Apperson
LHLotfi Hacein-Bey
Lotfi Hacein-Bey
VIVladimir Ivanovic
Vladimir Ivanovic
There is an extensive spectrum of autoimmune entities that can involve the central nervous system, which has expanded with the emergence of new imaging modalities and several clinicopathologic entities. Clinical presentation is usually non-specific, and imaging has a critical role in the workup of these diseases. Immune-mediated diseases of the brain are not common in daily practice for radiologists and, except for a few of them such as multiple sclerosis, there is a vague understanding about differentiating them from each other based on the radiological findings. In this review, we aim to provide a practical diagnostic approach based on the unique radiological findings for each disease. We hope our diagnostic approach will help radiologists expand their basic understanding of the discussed disease entities and narrow the differential diagnosis in specific clinical scenarios. An understanding of unique imaging features of these disorders, along with laboratory evaluation, may enable clinicians to decrease the need for tissue biopsy.

10 June 2016 in Journal of Neuroimmune Pharmacology
Verified
Journal Article
Closed access
PDF file
TSTyrell J. Simkins
Tyrell J. Simkins
DFDavid Fried
David Fried
KPKevin Parikh
Kevin Parikh
JGJames J. Galligan
James J. Galligan
JGJohn L. Goudreau
John L. Goudreau
BKBarbara Kaplan
Barbara Kaplan

30 May 2023 in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Verified
Journal Article
Open access
JSJeremy M. Shefner
Jeremy M. Shefner
AAAmmar Al-Chalabi
Ammar Al-Chalabi
JAJinsy A. Andrews
Jinsy A. Andrews
ACAdriano Chiò
Adriano Chiò
Mamede De CarvalhoMamede De Carvalho
Mamede De Carvalho
SRStacy A. Rudnicki
Stacy A. Rudnicki
Objective: To determine the target population and optimize the study design of the phase 3 clinical trial evaluating reldesemtiv in participants with amyotrophic lateral sclerosis (ALS).Methods: We evaluated the phase 2 study of reldesemtiv, FORTITUDE-ALS, to inform eligibility criteria and design features that would increase trial efficiency and reduce participant burden of the phase 3 trial.Results: In FORTITUDE-ALS, the effect of reldesemtiv was particularly evident among participants in the intermediate- and fast-progressing tertiles for pre-study disease progression. These participants most often had symptom onset <= 24 months and an ALS Functional Rating Scale-Revised (ALSFRS-R) total score <= 44 at baseline. Compared with the overall FORTITUDE-ALS population, the subgroup meeting these criteria declined by fewer ALSFRS-R points at 12 weeks (difference of least-squares mean [SE] versus placebo 1.84 [0.49] and 0.87 [0.35] for the overall population). These inclusion criteria will be used for the phase 3 clinical trial, COURAGE-ALS, in which the primary outcome is the change in ALSFRS-R total score at week 24. We also measure durable medical equipment use and evaluate strength in muscles expected to change rapidly. To reduce participant burden, study visits are often remote, and strength evaluation is simplified to reduce time and effort.Conclusions: In COURAGE-ALS, the phase 3 clinical trial to evaluate reldesemtiv, the sensitivity of detecting a potential treatment effect may be increased by defining eligibility criteria that limit the proportion of participants who have slower disease progression. Implementing remote visits and simplifying strength measurements will reduce both site and participant burden.ClinicalTrials.gov identifiers: NCT03160898 (FORTITUDE-ALS) and NCT04944784 (COURAGE-ALS)